Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares Bought by JPMorgan Chase & Co.

JPMorgan Chase & Co. grew its holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 1.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,069,117 shares of the biopharmaceutical company’s stock after acquiring an additional 19,588 shares during the quarter. JPMorgan Chase & Co. owned 1.05% of Esperion Therapeutics worth $3,414,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Xponance Inc. acquired a new position in shares of Esperion Therapeutics in the 2nd quarter valued at $28,000. Traphagen Investment Advisors LLC purchased a new stake in Esperion Therapeutics during the 3rd quarter valued at about $27,000. American Century Companies Inc. acquired a new position in shares of Esperion Therapeutics in the second quarter valued at about $50,000. Versor Investments LP purchased a new position in shares of Esperion Therapeutics in the third quarter worth about $44,000. Finally, Boomfish Wealth Group LLC lifted its holdings in shares of Esperion Therapeutics by 17.1% during the third quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company’s stock worth $58,000 after purchasing an additional 5,102 shares during the period. Institutional investors and hedge funds own 47.39% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ESPR. The Goldman Sachs Group initiated coverage on shares of Esperion Therapeutics in a report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price target on the stock. Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 target price for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price target on shares of Esperion Therapeutics in a report on Friday, December 13th. StockNews.com lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, HC Wainwright restated a “buy” rating on shares of Esperion Therapeutics in a research note on Friday, January 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Esperion Therapeutics has a consensus rating of “Hold” and an average price target of $7.30.

Esperion Therapeutics Stock Performance

Shares of Esperion Therapeutics stock opened at $2.21 on Friday. The firm has a 50-day simple moving average of $2.47 and a two-hundred day simple moving average of $2.18. Esperion Therapeutics, Inc. has a fifty-two week low of $1.58 and a fifty-two week high of $3.94. The company has a market cap of $435.46 million, a P/E ratio of -3.45, a price-to-earnings-growth ratio of 0.17 and a beta of 1.03.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.